Literature DB >> 22232752

Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function.

Matthew M Riggs1, Mark C Peterson, Marc R Gastonguay.   

Abstract

A physiologically based, multiscale model of calcium homeostasis and bone remodeling was used to describe the impact of progressive loss of kidney function over a typical 10-year course of chronic kidney disease (CKD), including the evolution of secondary hyperparathyroidism (HPT) caused by diminished renal phosphate clearance and increased plasma phosphate. An important sequela of HPT is marked elevations in bone resorption and loss of bone mineral density (BMD). Clinically, this CKD-related disease state is described as mineral bone disorder, or CKD-MBD. A multiscale physiologic model previously had been shown to describe CKD-MBD-related clinical changes in phosphate, parathyroid hormone (PTH), and calcitriol. The authors have extended the model to link bone remodeling markers with BMD elimination (0.000145 h(-1)) and formation rates. The composite model predicted lumbar spine BMD losses, relative to baseline, at months 28 (glomerular filtration rate = 58 mL/min), 50 (39 mL/min), and 120 (16 mL/min) of approximately -0.98%, -3.0%, and -6.5%, respectively, compared to the observed BMD values in corresponding renal function groups, scaled to a 100-mL/min baseline, of -0.5%, -4.0%, and -8.1%, respectively. In addition, simulated interventions with a hypothetical calcimimetic agent and calcitriol are provided to show the utility of this model as a platform for evaluating therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232752     DOI: 10.1177/0091270011412967

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

Review 1.  Pharmacometrics and systems pharmacology for metabolic bone diseases.

Authors:  Matthew M Riggs; Serge Cremers
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

2.  Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Authors:  Ping Chen; Adimoolam Narayanan; Benjamin Wu; Per Olsson Gisleskog; John P Gibbs; Andrew T Chow; Murad Melhem
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

3.  Application of a mechanism-based disease systems model for osteoporosis to clinical data.

Authors:  Teun M Post; Stephan Schmidt; Lambertus A Peletier; Rik de Greef; Thomas Kerbusch; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-12       Impact factor: 2.745

Review 4.  Advanced computational workflow for the multi-scale modeling of the bone metabolic processes.

Authors:  Tien Tuan Dao
Journal:  Med Biol Eng Comput       Date:  2016-09-16       Impact factor: 2.602

Review 5.  Pharmacology of bisphosphonates.

Authors:  Serge Cremers; Matthew T Drake; F Hal Ebetino; John P Bilezikian; R Graham G Russell
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

6.  Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.

Authors:  M C Peterson; M M Riggs
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-11-14

7.  Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.

Authors:  M M Riggs; M Bennetts; P H van der Graaf; S W Martin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-10-17

8.  Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Authors:  P Chen; P Olsson Gisleskog; J J Perez-Ruixo; J Xiao; J Wilkins; A Narayanan; J P Gibbs; M Melhem
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-09-17

9.  Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis.

Authors:  J Berkhout; J A Stone; K M Verhamme; B H Stricker; M C Sturkenboom; M Danhof; T M Post
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-08-22

10.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

Authors:  M C Peterson; M M Riggs
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.